Recommendations of the Czech Society for Rheumatology for the diagnosis and treatment of giant cell arteritis
Authors:
R. Bečvář; Výbor České Revmatologické Společnosti
Authors‘ workplace:
Revmatologický ústav Praha
Published in:
Čes. Revmatol., 30, 2022, No. 2, p. 54-59.
Category:
Recomendation
Overview
Bečvář R and the Committee of the Czech Society for Rheumatology. Recommendations of the Czech Society for Rheumatology for the diagnosis and treatment of giant cell arteritis Giant cell arteritis (GCA) is the most common primary vasculitis. Visual loss occurs in up to one-fifth of patients, which may be preventable by prompt recognition and glucocorticoid treatment. Suspicion of GCA should be confirmed using imaging methods or biopsy of the temporal artery. In selected patients with GCA with refractory or relapsing disease, the presence of an increased risk for glucocorticoid-related adverse events or internal comorbidities, tocilizumab or methotrexate should be added. The routine use of antiplatelet or anticoagulant therapy for GCA treatment is not recommended unless indicated for other reasons.
Keywords:
glucocorticoids – giant cell arteriiis – visual loss – immunosuppressants
Sources
- Gonzalez-Gay MA, Vazquez-Rodriguez TR, Lopez-Diaz MJ, et al.Epidemiology of giant cell arteritis and polymyalgia rheumatica.Arthritis Rheum 2009; 61: 1454–1461.
- Dejaco C, Duftner C, Buttgereit F, Matteson EL, Dasgupta B. The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease. Rheumatology (Oxford) 2017; 56: 506–515.
- Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR Standards, Guidelines and Audit Working Group. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 2010; 49: 1594–1597.
- Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG. Visual prognosis in giant cell arteritis. Ophthalmology 1993; 100: 550–555.
- Mukhtyar C, Guillevin L, Cid MC, et al. EULAR 5. recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318–323.
- Durling B, Toren A, Patel V et al. Jordan D. Incidence of discordant temporal artery biopsy in the diagnosis of giant cell arteritis. Can J Ophthalmol 2014; 49: 157–161.
- Dejaco C, Ramiro S, Duftner C. EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018; 77: 636–643.
- Duftner C, Dejaco C, Sepriano A, et al. Imaging in diagnosis, outcome prediction and monitoring of large vessel vasculitis: a systematic literature review and meta-analysis Informing the EULAR recommendations. RMD Open 2018; 4: e000612.
- Bley TA, Reinhard M, Hauenstein C, et al. Comparison of duplex sonography and high-resolution magnetic resonance imaging in the diagnosis of giant cell (temporal) arteritis. Arthritis Rheum 2008; 58: 2574–2578.
- Hay B, Mariano-Goulart D, Bourdon A, Benkiran M, Vauchot F, de Verbizier D, et al. Diagnostic performance of 18F-FDG PET-CT for large vessel involvement assessment in patients with suspected giant cell arteritis and negative temporal artery biopsy. Ann Nucl Med 2019; 33: 512–520.
- Maz M, Chung SA, Abril A, et al. 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis. Arthritis Rheumatol 2021; 73: 1349–1365.
- Hellmich B, Agueda A, Monti S, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2020; 79: 19–30.
- Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: an individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789–2797.
- Stone JH, Tuckwell K, Di Monaco S, Klearman M, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017; 377: 317–328.
- Leon L, Rodriguez-Rodriguez L, Freites D, et al. Long-term continuation of methotrexate therapy in giant cell arteritis patients in clinical practice. Clin Exp Rheumatol 2017; Suppl 103:165–170.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2022 Issue 2
Most read in this issue
- Approach to a patient with elevated serum creatine kinase
- Recommendations of the Czech Society for Rheumatology for the diagnosis and treatment of giant cell arteritis
- IL-40 – a new cytokine in the pathogenesis of rheumatic diseases
- Abstracts of the XVIII. seminar of young rheumatologists (Mikulov, May 26th–28th 2022)